Clinical trial
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic…
NCT00015847 · OHSU Knight Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00015847 |
|---|---|
| Title | Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia |
| Official title | A Phase I/II Dose-Finding Study to Determine the Safety, Tolerability, and Anti-Leukemic Effects of STI571 (NSC 716051) in Combination With Interferon-alpha in Patients With Chronic Myelogenous Leukemia in Chronic Phase |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug |
| Interventions | recombinant interferon alfa, imatinib mesylate |
| Enrollment | 25 |
| Start date | Apr 1, 2001 |
| Primary completion | May 1, 2011 |
| Completion | May 1, 2011 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 22, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: